COMPARISON OF EFFICACY OF TAZAROTENE/BETAMETHASONE VERSUS CALCIPOTRIOL/BETAMETHASONE IN PATIENTS WITH MILD TO MODERATE PLAQUE PSORIASIS

S AMIN; MR KHAN; M SALEEM; A KHAN; F MUSHTAQ

doi:10.54112/bcsrj.v2024i1.1088

Authors

S AMIN Department Of Dermatology PIMS, Islamabad, Pakistan
MR KHAN Department Of Dermatology PIMS, Islamabad, Pakistan
M SALEEM Department Of Dermatology PIMS, Islamabad, Pakistan
A KHAN Department Of Dermatology PIMS, Islamabad, Pakistan
F MUSHTAQ Department Of Dermatology PIMS, Islamabad, Pakistan

DOI:

https://doi.org/10.54112/bcsrj.v2024i1.1088

Keywords:

Plaque psoriasis, Calcipotriol, Tazarotene, PASI scores

Abstract

Plaque psoriasis is a chronic inflammatory skin disorder that significantly impacts patients' quality of life. Combination therapies, such as Tazarotene/Betamethasone and Calcipotriol/Betamethasone, are widely used for its management. Evaluating the efficacy of these combination therapies is essential for optimizing treatment outcomes. Objective: To evaluate the efficacy of Tazarotene/Betamethasone compared to Calcipotriol/Betamethasone in patients with mild to moderate plaque psoriasis. Methods:

Following ethical committee approval, this randomized comparative study was conducted in the Department of Dermatology, PIMS, Islamabad, from January 2024 to June 2024. One hundred seventy patients with mild to moderate plaque psoriasis were enrolled and randomly assigned to two groups. Group A received Tazarotene 0.045% cream combined with Betamethasone dipropionate 0.05% ointment, while Group B was treated with Calcipotriol 0.005% combined with Betamethasone dipropionate 0.05% ointment. Both therapies were applied once daily for 12 weeks. The treatment response was assessed by evaluating changes in the Psoriasis Area and Severity Index (PASI) scores and Body Surface Area (BSA) affected. Data were analyzed using SPSS Version 26, and comparisons between the groups were made using t-tests, with significance set at p < 0.05. Results: The mean age of participants was 39.52±11.07 years. In Group A, 35.3% were male and 64.7% were female, while in Group B, 41.2% were male and 58.8% were female. Baseline PASI scores and BSA affected were comparable between the groups. After 12 weeks, Group A showed a more significant reduction in PASI scores (4.72±1.01 vs. 5.20±0.93, p=0.00) and BSA affected (3.49±0.86% vs. 4.21±0.86%, p=0.00) compared to Group B. Conclusion: Both combination therapies resulted in significant improvements in PASI scores and reductions in BSA affected. However, Tazarotene/Betamethasone was more effective than Calcipotriol/Betamethasone, likely due to the keratolytic properties of Tazarotene. These findings suggest that Tazarotene/Betamethasone may offer superior efficacy in managing mild to moderate plaque psoriasis.

Downloads

Download data is not yet available.

References

Bélanger A, de Oliveira CP, Maheux M, Pouliot R. Plaque psoriasis: understanding risk factors of this inflammatory skin pathology. Journal of Cosmetics, Dermatological Sciences and Applications. 2016;6(02):67.

Nabieva K, Vender R. Quality of life and body region affected by psoriasis: a systematic review. Actas dermo-sifiliograficas. 2023;114(1):33-8.

Bhosle MJ, Kulkarni A, Feldman SR, Balkrishnan R. Quality of life in patients with psoriasis. Health and quality of life outcomes. 2006;4:1-7.

Lesuis N, Befrits R, Nyberg F, van Vollenhoven RF. Gender and the treatment of immune-mediated chronic inflammatory diseases: rheumatoid arthritis, inflammatory bowel disease and psoriasis: an observational study. BMC medicine. 2012;10:1-9.

Afreen H, Islam AS, Alam MN, Afroz F, Sultana T. A comparative study of once daily tazarotene versus combination of tazarotene and betamethasone valerate in the treatment of plaque psoriasis. Journal of Pakistan Association of Dermatologists. 2019;29(1):93-100.

Kuchekar AB, Pujari RR, Kuchekar SB, Dhole SN, Mule PM, Vidyapeeth B, et al. Psoriasis: A comprehensive review. Int J Pharm Life Sci. 2011;2(6):857-77.

Goldsmith LA, Fitzpatrick TB, Katz SI, Gilchrest BA, Paller AS, Leffell DJ, et al. Fitzpatrick's dermatology in general medicine. (No Title). 2012.

Henseler T, Schmitt‐Rau K. A comparison between BSA, PASI, PLASI and SAPASI as measures of disease severity and improvement by therapy in patients with psoriasis. International journal of dermatology. 2008;47(10):1019-23.

Gelfand JM, Feldman SR, Stern RS, Thomas J, Rolstad T, Margolis DJ. Determinants of quality of life in patients with psoriasis: a study from the US population. Journal of the American Academy of Dermatology. 2004;51(5):704-8.

Mrowietz U, Steinz K, Gerdes S. Psoriasis: to treat or to manage? Experimental dermatology. 2014;23(10):705-9.

Chen Y, Yi M, Pang X, Du M, Chen H, Li Z. Effects of secukinumab combined with tretinoin on metabolism, liver enzymes, and inflammatory factors in patients with moderate to severe psoriasis vulgaris. Advances in Dermatology and Allergology/Postępy Dermatologii i Alergologii. 2024;41(1):113-20.

Tada Y, Ishii K, Kimura J, Hanada K, Kawaguchi I. Patient preference for biologic treatments of psoriasis in Japan. The Journal of dermatology. 2019;46(6):466-77.

Schaarschmidt ML, Umar N, Schmieder A, Terris D, Goebeler M, Goerdt S, et al. Patient preferences for psoriasis treatments: impact of treatment experience. Journal of the European Academy of Dermatology and Venereology. 2013;27(2):187-98.

Navarro-Triviño FJ, Lozano-Lozano M, Ruiz-Villaverde R. Calcipotriol/betamethasone dipropionate aerosol foam for plaque psoriasis: a prospective, observational, non-interventional, single-center study of patient adherence and satisfaction in daily use. Dermatology Practical & Conceptual. 2021;11(3).

Norris DA. Mechanisms of action of topical therapies and the rationale for combination therapy. Journal of the American Academy of Dermatology. 2005;53(1):S17-S25.

Heath MS, Sahni DR, Curry ZA, Feldman SR. Pharmacokinetics of tazarotene and acitretin in psoriasis. Expert opinion on drug metabolism & toxicology. 2018;14(9):919-27.